September 1st, 2012, VAXON-Biotech announces that the first patient has been randomized in the multicenter Phase IIb trial (Vx-001-201) for the treatment of non-small-cell lung cancer with the therapeutic cancer vaccine Vx-001.

February 28th, 2012 : VAXON-Biotech announces that two patent applications covering Vx-001 and Vx-006 vaccines have been granted in China and Japan respectively

August 30th, 2011 VAXON-Biotech announces publication of two articles in Cancer Immunology Immunotherapy and in Annals of Oncology presenting immunological and clinical data in cancer patients vaccinated with Vx-001

Ann. Oncol., 2012, 23: 442-9

Cancer Immunol. Immunother., 2012, 61: 157-68

20/02/09 : VAXON-Biotech's lead product, Vx-001, has been granted orphan drug status by FDA for the treatment of NSCLC for HLA-A2+ patients with TERT+ tumours

30/05/08 : VAXON-Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the ASCO 2008 Annual Meeting

To download ASCO 2008 Abstract click here

11/04/08 : VAXON-Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the 99th AACR Annual Meeting

To download American / English version click here

To download American / English version click here

Télécharger la version française en cliquant ici 

 To download American / English version click here

03/06/07 : VAXON-Biotech Presents Preliminary Results from Vx-001 Vaccine Clinical Trial on Lung Cancer at the ASCO 2007 annual meeting

 To download American / English version click here

03/04/06 : VAXON-Biotech and Institut Pasteur Announce Collaboration to Develop New Products and Models for Cancer Immunotherapy 

To download American / English version click here

14/03/06 : VAXON-Biotech to Present Latest Clinical Data of its Vx-001 Cancer Vaccine at the 97^th AACR Annual Meeting

To download American / English version click here